Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Conclusions
This phase 2b clinical trial met the primary endpoint. All telitacicept groups showed a significantly higher proportion of patients achieving an SRI-4 response than the placebo group at week 48, and all doses were well tolerated. These results support further investigations of telitacicept in clinical trials involving more diverse populations and larger sample sizes.

Trial registration number
ClinicalTrials.gov Registry (NCT02885610).

Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Wu, D., Li, J., Xu, D., Merrill, J. T., van Vollenhoven, R. F., Liu, Y., Hu, J., Li, Y., Li, F., Huang, C., Wang, G., Li, X., Zhao, J., Zhao, D., Huang, C., Liu, H., Wei, W., Shi, G., Lu, F., Zuo, X., Bi, L., Li, Z., Wang, X., Zhang, M., Tie, N., Li, J., Tags: Open access, ARD, Systemic Lupus erythematosus Source Type: research